Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BA3241
- Development stage
- Preclinical
- Lead developer
- BioAtla
- Modality
- Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BA3241 is a Conditionally Active Biologic (CAB) monoclonal antibody of the IgG2 isotype that targets Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), developed by BioAtla. Utilizing BioAtla's proprietary CAB technology, BA3241 is engineered to selectively bind CTLA-4 in the acidic microenvironment of tumors (low pH) while remaining largely inactive at the physiological pH of healthy tissues. This tumor-selective binding is intended to improve the safety profile of CTLA-4 inhibition by reducing systemic immune-related adverse events (irAEs) while maintaining potent anti-tumor efficacy. BA3241 was evaluated as an alternative isotype candidate to BioAtla's lead clinical CAB-CTLA-4 antibody, BA3071 (an IgG1 isotype), for the treatment of various solid tumors.
- Other names
- CAB-CTLA-4 antibodyCAB-CTLA4 antibodyCAB-CTLA 4 antibodyCAB-CTLA4CAB-CTLA-4CAB-CTLA 4
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on BA3241.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BA3241.